Herceptin Biosimilar Market - (By Application - Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma Market By End Users- Hospital & Clinics, Oncology Centers) - Global Industry Size, Share, Trends, and Forecast, 2018-2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 150

Introduction

Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein. In 2014, herceptin has lost the patent in Japan and Europe which has opened the gates for the development of the biosimilar to enter the market.  Whereas, the patent for the drug in U.S. will expire in 2019. The companies are continuously trying to introduce the new generic drugs to expand their market.

Market Dynamics

During last few years, there is a significant rise in the cancer patient pool. Increasing prevalence of the cancer and increasing demand for the targeted therapy have led to drive the growth of the market. Breast cancer is the most widely occurred cancer in the woman. According to the U.S. breast cancer Statistics, over 12.4% of the total American woman develops breast cancer in their lifetime. Changing lifestyle, increasing pollution and adoption of smoking by the people has fuelled the growth of the market. As there are huge opportunity for the development of the cancer drug a number of companies are continuously investing a huge amount of capital in research and development. Increasing spending on research & development and increasing demand for the better drugs for the treatment has supported and created a huge opportunity in coming future.

On the other hand, availability of the alternative treatment and huge side effects of the drugs may slow the growth of the market during the forecasted period.

Market Classification and Overview

The global herceptin biosimilar market is segment into application, end-user, and region.

On the basis of application, the market is segmented into breast cancer, colorectal cancer, leukemia, lymphoma, and others.

Based on the end-user, the market is segmented into hospital & clinics, oncology centers, and others.

Regional Overview

Geographically, the global herceptin biosimilar market is segmented into : North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

Europe dominates the global herceptin biosimilar market owing to the patent expiry of the drug in Europe. In 2014, herceptin biosimilar has lost the patent which has increased the market for the generics of the herceptin. Additionally, introduction of the new generics products in European market and continuous research & development in the drug discovery has boosted the growth of the market in Europe. Asia Pacific holds the second position followed by America. The Asia Pacific herceptin biosimilar market is majorly driven by rapid adoption of the herceptin biosimilar, increasing awareness about the generic products, and huge patient pool. Japan is expected to hold the major share in the market owing to the patient expiry of herceptin in 2014. However, LAMEA holds the last position in the market owing to the limited spending on the healthcare and Research & Development.

Report Coverage

Market

Herceptin Biosimilar Market

Analysis Period

2015 – 2026

Historic Data

2015 – 2016

Base Year

2017

Forecast Data

2018 – 2026

Market Stratification

 Application, End Users, Geography

Regional Scope

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

Report Coverage

Market Trends, Drivers, Restraints, Porter's Five Forces Analysis,

Competitive Analysis, Player Profiling, Value Chain Analysis

Market Participants

The global herceptin biosimilar market comprises of some of the major players such as

  • Mylan
  • Biocon
  • Roche
  • others

Currently limited numbers of companies are present in the market. Herceptin was developed by Roche and is still holding the patient in some of the countries. However, the companies like Pfizer, TEVA and others are continuously trying to develop the new generic drugs so as to enter in the market. With the expiry of the patent for the drug in 2019, the herceptin biosimilar market will possess a huge growth.

Market Segmentation

Market By Application

  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lymphoma
  • Others

Market  By End-User

  • Hospital & Clinics
  • Oncology Centers
  • Others

Market By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

 


FAQ

Next Generation sequencing Market (By Products and Services: NGS Platforms & Related Products, NGS Services; By Application: Oncology, Reproductive Health, Clinical Investigation, Immune System Monitoring, Agriculture & Animal Research, Epidemiology & Drug Development, Consumer Genomics; By Technology: Whole Genome Sequencing, Targeted Sequencing & Resequencing, Whole Exome Sequencing; By End Users: Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other users) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The Global Next Generation Sequencing Market is expected to grow at a CAGR of around 18.7% over the forecast period 2019 to 2026 and poised to reach around US$ 20.4 Bn by 2026. Next Generation Sequencing (NGS) is a platform that enabled the sequencing of thousands to millions DNA molecules simultaneously. It is also known as the massively parallel sequencing technology. This sequencing helps in the various fie

Ultrasound Equipment Market (By Portability: Trolley/Cart-based, Compact, Handheld; By Application: Obstetrics/Gynecology, General Imaging, Vascular Applications, Cardiologic Applications, Orthopedic Applications, Urological Applications, Pain Management, Others; By Equipment Display: Black & White, Color; By Technology: Therapeutic, Diagnostic) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The global ultrasound equipment market is expected to grow at a CAGR of around 6.3% from 2019 to 2026 and expected to reach the market value of around US$ 10 Bn by 2026. Ultrasound is a medical imaging technology that uses sound waves to produce pictures of body’s inside part. It helps to diagnose swelling, pain, and infection in internal organs and to examine a baby in pregnant women. Ultrasound is also

Minimally Invasive Surgery Market (By Product: Handheld Instruments, Electrosurgical Instruments, Guiding Devices, Inflation Systems, Auxiliary Instruments, Cutter Instruments; By Application: Gastrointestinal Surgery, Cardiothoracic Surgery, Orthopedic Surgery, Gynecological Surgery, Cosmetic/Bariatric Surgery, Vascular Surgery, Urological Surgery, Others; By End User: Hospitals, Ambulatory Surgery Centers, Research Institutes) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The global minimally invasive surgery market is expected to grow at a CAGR of around 9.6% over the forecast period 2019 to 2026 and expected to reach the market value of around US$ 33.8 Bn by 2026. Minimally invasive surgery uses techniques to operate with less incision or damage to the body than open surgery. Hence, it is associated with less pain, fewer postoperative complications, and short

Implantable Medical Devices Market (By Product: Dental Implants, Breast Implants, Orthopedic Implants, Cardiovascular Implants, Intraocular Lens, Others) - Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The global implantable medical devices market is expected to grow at a CAGR of around 7.3% over the forecast period 2019 to 2026 and expected to reach the market value of around US$ 153.8 Bn by 2026. An implant is a medical device, manufactured to support or replace any damaged organs in the body, treat imperfections in normal body functions, or enhance the functioning of body organs. These can be implanted by

eClinical Solutions Market (By Product: Electronic Data Capture and Clinical Data Management Systems, Clinical Trial Management Systems; By Delivery Mode: Web-Hosted (On-Demand) Solutions, Licensed Enterprise (On-Premise) Solutions, Cloud-Based (SaaS) Solutions; By Clinical Trial Phase: Phase I Clinical Trials, Phase II Clinical Trials; By End-Use: Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Consulting Service Companies) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The Global eclinical Solutions Market is expected to grow at a CAGR of around 9.7% from 2019 to 2026 and expected to reach the market value of around US$ 9,756 Mn by 2026. The eclinical solutions refer to the development and offering of clinical technologies and expertise which are aimed at supporting the development of the clinical process. The eclinical solutions usually involve

Insulin Delivery Devices Market (By Type: Insulin Syringe, Insulin Pens, Insulin Jet Injectors, Insulin Pumps, Insulin Needles, Insulin Inhalers; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales, Diabetes Clinics & Centers; By End Use: Hospitals, Clinics, Ambulatory Care Centers, Homecare) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

The Global Insulin Delivery Devices Market value is expected to reach around US$ 22.5 Bn by 2026 and growing at a CAGR of around 7.2% over the forecast period 2019 to 2026. Insulin delivery devices are used to deliver insulin to patients with Type 1 and Type 2 diabetes. Insulin is an important part of treatment for the diabetes patient which helps them to get glucose from the blood

Cart Summary